Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29435084 | 1.00 | PARP1 (1.00) | PARP1 | |
| SCHEMBL21160645 | 0.85 | PARP1 (0.74) | PARP1 | |
| SCHEMBL21155625 | 0.82 | PARP1 (0.70) | PARP1 | |
| SCHEMBL14356191 | 0.79 | PARP1 (0.66) | PARP1 | |
| SCHEMBL14980870 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL21160642 | 0.74 | PARP1 (0.58) | PARP1 | |
| SCHEMBL21155204 | 0.72 | PARP1 (0.56) | PARP1 | |
| SCHEMBL12846284 | 0.71 | PARP1 (0.64) | PARP1 | |
| SCHEMBL12846160 | 0.69 | PARP1 (0.65) | PARP1 | |
| SCHEMBL12451944 | 0.68 | GAA (0.53) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | CYBREXA 1, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | ARQULE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | CYBREXA 1, INC. | 2019-07-11 | — | — | US | disclosed |
| US-9062043-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES, INC. (TW) | 2015-06-23 | — | — | US | disclosed |
| EP-2061765-B1 | Serine-threonine protein kinase and PARP modulators | SENHWA BIOSCIENCES INC (TW) | 2014-10-22 | — | — | EP | disclosed |
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7956064-B2 | Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7910600-B2 | Therapeutic kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009097014-A2 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263581-A1 | FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PARP1, PARP11, TNKS | PARP1 1/4885 |
| US-20200155521-A1 | PHARMACEUTICAL COMBINATION FOR TREATMENT OF CANCER | TP53, KRAS, VHL | PARP1 1298/4885 |
| US-20210299137-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | PARP1 1881/4885 |
| US-20090093465-A1 | THERAPEUTIC KINASE MODULATORS | PACSIN2, CKS1B, CSNK1A1 | PARP1 1797/4885 |
| US-20090264423-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885 |
| US-10933069-B2 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | HIF1A, HIF1AN, VHL | PARP1 1881/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | PARP1 3/4885 |
| US-20190209580-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DISEASES INVOLVING ACIDIC OR HYPOXIC DISEASED TISSUES | HIF1A, HIF1AN, VHL | PARP1 1881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.